Peripheral blood leukocyte counts in cytomegalovirus infected heart transplant patients: Impact of acute disease versus subclinical infection

Transplantation

Volumn 82, Issue 11, 2006, Pages 1419-1424

  Cooke, Margaret E ^a   Potena, Luciano ^a   Luikart, Helen ^a   Valantine, Hannah A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Heart transplantation; Infection; Leucopenia

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VIRUS DNA;

ACUTE DISEASE; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CELL POPULATION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MONOCYTOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AZATHIOPRINE; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FEMALE; HEART TRANSPLANTATION; HEMOGLOBINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 33845719060     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000242139.13197.7f     Document Type: Article

References (19)

1. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 2004; 4(2): 169.
2. Rubin RH. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000; 19(8): 731.
3. Petrakopoulou P, Kubrich M, Pehlivanli S, et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004; 110 (11 Suppl 1): II207.
4. Borchers AT, Perez R, Kaysen G, et al. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999; 7(2): 75.
5. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100(1): 61.
6. Hayry P, Lemstrom K, von Willebrand E, et al. CMV infection and allograft rejection. Transplant Proc 1998; 30(3): 916.
7. Koskinen P, Lemstrom K, Mattila S, et al. Cytomegalovirus infection associated accelerated heart allograft arteriosclerosis may impair the late function of the graft. Clin Transplant 1996; 10 (6 Pt 1): 487.
8. Koskinen PK, Kallio EA, Tikkanen JM, et al. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1(2): 115.
9. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261(24): 3561.
10. Potena L, Grigioni F, Ortolani P, et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003; 75(6): 839.
11. Mocarski ES Jr. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 2004; 6(8): 707.
12. Froberg MK. Review: CMV escapes! Ann Clin Lab Sci 2004; 34(2): 123.
13. Mocarski ES Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002; 10(7): 332.
14. Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995; 60(12): 1473.
15. Moreso F, Seron D, Morales JM, et al. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 1998; 12(3): 198.
16. Giesler G, Espejo M, Kubak B, et al. Increased risk of CMV infection in heart transplant patients on mycophenolate mofetil. J Heart Lung Transplant 2001; 20(2): 178.
17. Mori T, Nakamura M, Shimizu K, et al. In vivo disturbance of hematopoiesis in mice persistently infected with murine cytomegalovirus: impairment of stromal cell function. Virology 1999; 253(2): 145.
18. Yamani MH, Avery R, Mawhorter S, et al. Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transpl Infect Dis 2001; 3 Suppl 2: 40.
19. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33(7): E62.